Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16875799 | 0.93 | LMNA (0.49) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL2011397 | 0.93 | LMNA (0.49) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL622562 | 0.91 | LMNA (0.48) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8978121 | 0.91 | LMNA (0.47) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL30980833 | 0.90 | LMNA (0.47) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL21211562 | 0.87 | LMNA (0.49) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL7047230 | 0.87 | LMNA (0.51) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL11005886 | 0.85 | CYP2C19 (0.52) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL5031817 | 0.85 | LMNA (0.48) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL31463028 | 0.83 | LMNA (0.48) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354842-A | Improved preparation method of iomeprol and application of iomeprol in preparation | 重庆圣华曦药业股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-115298162-A | Continuous crystallization method | 通用电气医疗集团股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-112898177-B | Preparation method of iomeprol impurity | 浙江司太立制药股份有限公司 | 2022-06-17 | — | — | CN | claimed |
| EP-4001261-A1 | PROCEDURE FOR OBTAINING HIGH PURITY IOHEXOL | Justesa Imagen S.A.U (ES) | 2022-05-25 | — | — | EP | claimed |
| CN-110590591-B | Preparation method of iodixanol and iohexol impurities | 浙江海洲制药有限公司 | 2022-05-17 | — | — | CN | claimed |
| EP-0642492-B1 | 5,5'-/(1,3-PROPANEDIYL) BIS-/IMINO(2-OXO-2,1-ETHANEDIYL)ACETYLIMINO/BIS(2,4,6-TRIIODO-1,3-BENZENEDICARBOXYAMIDES), AND CONTRAST MEDIA CONTAINING THEM | BRACCO SPA (IT) | 1996-09-11 | — | — | EP | claimed |
| CN-114716339-B | Iodixanol Industrial preparation method | 安徽普利药业有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-115093342-B | Industrial production method of ioversol | 安徽普利药业有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119528755-A | Ioversol impurity and preparation method thereof | 江西司太立制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-116354842-B | Improved preparation method of iomeprol and application of iomeprol in preparation | 重庆圣华曦药业股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118108618-A | Production process of iodixanol | 成都倍特药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230384296-A1 | HIGHLY SENSITIVE PARTICLE ENHANCED ASSAY FOR THE QUANTIFICATION OF NT-PROBNP | GENTIAN AS (NO) | 2023-11-30 | — | — | US | disclosed |
| CN-117083262-A | Iodinated compounds with radiocontrast properties | 波士顿科学国际有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-2016046-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-11 | — | — | EP | disclosed |
| US-8066974-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-20090136425-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-05-28 | — | — | US | disclosed |
| EP-2016046-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007133088-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-11-22 | — | — | WO | disclosed |
| EP-0983230-B1 | YELLOW POLYMORPH OF 5-AMINO-2,4,6-TRIIODO-N,N'-BIS(2,3-DIHYDROXYPROPYL)-ISOPHTHALAMIDE | AMERSHAM HEALTH AS (NO) | 2003-12-10 | — | — | EP | disclosed |
| US-6337422-B1 | COMPOUND FORM IS ONE IN WHICH DIFFERENTIAL SCANNING CALORIMETRY HAS A PEAK MELTING TEMPERATURE OF 247-252 DEGREE C. | NYCOMED IMAGING AS (NO) | 2002-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136425-A1 | CONTRAST AGENTS | IPO8, IPO4, IPO11 | LMNA 1724/4885CYP2C19 4220/4885HIF1A 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.